Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Tablet Completes First Patient Dosing in Phase II Clinical Trial for Ankylosing Spondylitis
Published Time:
2023-05-04 17:35
Source:
The second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), recently initiated its Phase II clinical study for ankylosing spondylitis (AS). On April 26th, the first patient was successfully dosed at Peking University People's Hospital. VC005 Tablet demonstrated favorable metabolic properties, safety, and tolerability in the completed Phase I clinical study. Currently, in addition to the AS trial, multiple Phase II clinical studies for VC005 Tablet in oral treatment of conditions like atopic dermatitis are also being successively initiated.
About VC005
VC005 is a novel, highly potent, and selective second-generation JAK1 inhibitor independently developed by Jiangsu Vcare. By selectively inhibiting JAK1, the drug reduces inflammatory responses and immune cell activation, thereby achieving therapeutic effects in inflammatory and autoimmune diseases. Compared to Upadacitinib(a currently marketed JAK inhibitor), VC005 exhibits lower JAK2 inhibitory activity(based on in vitro kinase assays), which may mitigate safety concerns associated with excessive JAK2 inhibition. The drug is currently being developed in two formulations: oral tablets and topical gel.
About JAK1
The JAK/STAT signaling pathway, mediated by JAK family kinases and downstream STAT transcription factors, plays a critical regulatory role in inflammatory and autoimmune diseases such as AS and AD. Current first-generation pan-JAK inhibitors non-selectively inhibit multiple JAK subtypes (e.g., JAK1, JAK2,TYK2) at similar potency levels. Excessive JAK2 inhibition is associated with severe adverse events, prompting the U.S. FDA to issue black box warnings for these agents. Consequently, second-generation selective JAK1 inhibitors like VC005, designed for enhanced safety and efficacy, represent a necessary evolution in therapy.
About AS
AS is a chronic inflammatory disease primarily affecting the sacroiliac joints, spine, paravertebral soft tissues, and peripheral joints, potentially causing structural damage, spinal deformity, and disability.
Prevalence: The Prevalence of AS in China is approximately 0.36%, affecting over 5 million individuals. Demographics: AS predominantly affects males aged between 15–40, with onset typically occur before the age of 35. Pathogenesis: The pathogenesis of AS is associated with genetic, infectious, environmental, and immunological factors. The disease progresses over time, often resulting in irreversible damage. Treatment: JAK inhibitors, which are non-immunogenic small-molecule drugs, avoid secondary failure caused by neutralizing antibodies (common with biologics), offering a promising therapeutic approach.
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn